Problematic COVID-19 preprint articles
| Source | Issue | Location of corresponding author’s institution | Finding |
| SSRN 21 | Dataset is linked to two other retracted papers22 23 | USA | Retracted |
| SSRN 24 | Dataset is linked to two other retracted papers22 23 | USA | Retracted |
| SSRN 25 26 | Numerous concerns including authorship, statistical analysis, findings | Indonesia | Retracted |
| bioRxiv 27 | Article lacked the full consent for publication by all authors | China | Withdrawn |
| bioRxiv 28 | Authors' desire to perform additional research to validate their work | China | Withdrawn |
| medRxiv 29 | Authors' desire to update their dataset to enlarge it | China | Withdrawn |
| medRxiv 30 | Authors' desire to perform additional research to validate their work | China | Withdrawn |
| bioRxiv 31 | Consent was not obtained for use of the study dataset | Bangladesh | Withdrawn |
| medRxiv 32 | Controversy about hydroxychloroquine and a retrospective study design | France | Withdrawn |
| bioRxiv 33 | Concerns regarding technical approach and data interpretation | India | Withdrawn |
| medRxiv 34 | Study performed beyond scope of the research ethics committee approval | Italy | Withdrawn |
| medRxiv 35 | Study performed beyond scope of the research ethics committee approval | Italy | Withdrawn |
| medRxiv 36 | Controversy about hydroxychloroquine; results potentially different after peer review. | South Korea | Withdrawn |
| medRxiv 37 | Privacy concerns regarding research participants | USA | Withdrawn |